Skip to content

A clinical study to evaluate the benefits of frequent AV/PV and V-V delay optimization using QuickOptTM in patients with CRT-D devices.

OPTIMISE CRT - Optimal Programming To Improve Mechanical Indices, Symptoms And Exercise In Cardiac Resynchronization Therapy

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2009/091/000775
Enrollment
450
Registered
2009-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Heart Failure

Interventions

Intervention1: Patient Implanted with CRT-D Device and AV/PV and V-V delays optimized using Quick-Opt.: Patient Implanted with CRT-D Device programmed to sequential BiV pacing mode with AV/PV and V-V

Sponsors

SJM International Inc
Lead Sponsor
St. Jude Medical (HK) Ltd. Suite 1608, 16/F Exchange Tower 33 Wang Chiu Road Kowloon Bay, Kowloon Hong Kong SAR
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. CRT-D indications and be implanted with an SJM CRT-D device with VV timing and a compatible lead system. 2. Able to complete a 6-minute hall walk with the only limiting factor to be fatigue or shortness of breath. 3. Geographically stable and willing to comply with follow-up. 4. Adequate echocardiographic images to measure LV end systolic volume.

Exclusion criteria

Exclusion criteria: 1. Epicardial ventricular lead system. 2. Ability to walk ≥ 450 meters in 6 minutes 3. Limited intrinsic atrial activity (≤ 40 bpm). 4. Persistent or permanent AF. 5. 2° or 3° heart block. 6. Life expectancy is less than 1 year. 7. Patient is pregnant. 8. Receiving IV inotropic agents.

Design outcomes

Primary

MeasureTime frame
Clinical benefit (reduction in SAS of at least 1 class or a 25% or larger improvement in 6 minute hall walk distance) plus structural remodeling (15% or greater reduction in left LV end systolic volume or ≥ 5% absolute improvement in echo-derived LV EF)Timepoint: Time Frame: 12 months

Secondary

MeasureTime frame
1)Rate of late (12-month) versus early (3 month) response to CRT Rate of late (12-month) versus early (3 month) response to CRT 2)Changes in BNP 3)Inter-/intra-ventricular dysynchronyTimepoint: Time Frame: 3 and 12 months

Countries

India

Contacts

Public ContactSumit Anand

St. Jude Medical India Pvt. Ltd.

sanand@sjm.com918860661364

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026